Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
280- ALA,    Alpha‐lipoic acid inhibits lung cancer growth via mTOR‐mediated autophagy inhibition
- in-vivo, Lung, A549
p‑mTOR↑, TumCG↓, TumAuto↓, p‑P70S6K↑,
281- ALA,    Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation
- in-vitro, Lung, H460
mt-ROS↑, Apoptosis↑, Casp9↑, Bcl-2↓, eff↓, eff↑, H2O2↑, Dose↑,
290- ALA,  HCA,    A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results
- vitro+vivo, Melanoma, B16-F10
TumCG↓, OS↑,
291- ALA,  HCA,  MET,  Dicl,    Metabolic therapies inhibit tumor growth in vivo and in silico
- in-vivo, Melanoma, B16-F10 - in-vivo, Lung, LL/2 (LLC1) - in-vivo, Bladder, MBT-2
TumCG↓,
295- ALA,    α-Lipoic acid suppresses migration and invasion via downregulation of cell surface β1-integrin expression in bladder cancer cells
- in-vitro, Bladder, T24/HTB-9
ITGB1↓, TumCMig↓, ERK↓, Akt↓,
296- ALA,    Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo
- vitro+vivo, neuroblastoma, SK-N-SH - vitro+vivo, BC, SkBr3
TumCG↓, Casp3↑,
297- ALA,    Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
- Review, BC, SkBr3 - Review, neuroblastoma, SK-N-SH - Review, AD, NA
PDH↑, TumCG↓, ROS↑, AMPK↑, EGR4↓, Half-Life↓, BioAv↝, *GSH↑, *IronCh↑, *ROS↓, *antiOx↑, *neuroP↑, *Ach↑, *lipid-P↓, *IL1β↓, *IL6↓, TumCP↓, FDG↓, Apoptosis↑, AMPK↑, mTOR↓, EGFR↓, TumCI↓, TumCMig↓, *memory↑, *BioAv↑, *BioAv↝, *other↓, *other↝, *Half-Life↓, *BioAv↑, *ChAT↑, *GlucoseCon↑,
298- ALA,  Rad,    Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1
- in-vitro, BC, MDA-MB-231
Apoptosis↑, P53↑, p38↑, NF-kB↑, TumCCA↑,
299- ALA,  Cisplatin,  PacT,    Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line
- in-vitro, Ovarian, OVCAR-3
MMP9↓, MMP11↓, MAPK↓,
301- ALA,  PacT,  doxoR,    Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients
- Human, BC, NA
BNP↓, TNF-α↓, MDA↓, NeuroT↓,
302- ALA,    The Antioxidant Alpha-Lipoic Acid Inhibits Proliferation and Invasion of Human Gastric Cancer Cells via Suppression of STAT3-Mediated MUC4 Gene Expression
- in-vitro, GC, AGS - in-vitro, GC, BGC-823 - in-vitro, GC, MKN-28
MUC4↓, STAT3↓,
303- ALA,  LDN,    The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol

304- ALA,    alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation
- in-vitro, Colon, HT-29
mt-ROS↑, Apoptosis↑, Casp3↑, DNAdam↑, Bcl-xL↓, Dose↝,
272- ALA,    Evidence that α-lipoic acid inhibits NF-κB activation independent of its antioxidant function
- in-vitro, NA, HUVECs
NF-kB↓,
266- ALA,    Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death
- in-vitro, Ovarian, IGROV1
Mcl-1↓, Bcl-xL↓, BIM↑, ROS↑,
259- ALA,    Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells
- in-vitro, Liver, HepG2 - in-vitro, Liver, FaO
Cyc↓, P21↑, ROS↑, p‑P53↑, BAX↑, Cyt‑c↑, Casp↑, survivin↓, JNK↑, Akt↓,
260- ALA,    The effects of alpha-lipoic acid on breast of female albino rats exposed to malathion: Histopathological and immunohistochemical study
- in-vivo, BC, NA
PCNA↓, P53↓, Apoptosis↑, BAX↑,
261- ALA,    The natural antioxidant alpha-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells
- in-vitro, BC, MCF-7
ROS↓, Akt↓, p27↑, Bax:Bcl2↑,
258- ALA,    Effects of α-lipoic acid on cell proliferation and apoptosis in MDA-MB-231 human breast cells
- in-vitro, BC, MDA-MB-231
TumCG↓, p‑Akt↓, Akt↓, HER2/EBBR2↓, Bcl-2↓, BAX↑, Casp3↑,
262- ALA,    Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
TumCP↓, Akt↓, ERK↓, IGF-1R↓, Furin↓, Ki-67↓, AMPK↑, mTOR↓,
263- ALA,    Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines
- in-vitro, SCC, Jurkat - in-vitro, SCC, FaDu
p27↑,
264- ALA,    α-Lipoic acid induces Endoplasmic Reticulum stress-mediated apoptosis in hepatoma cells
- in-vitro, HCC, FaO
ROS↑, P53↑, ER Stress↑, UPR↑, CHOP↑, PDI↑, GRP78/BiP↑, GRP58↓,
265- ALA,    Alpha-Lipoic Acid Reduces Cell Growth, Inhibits Autophagy, and Counteracts Prostate Cancer Cell Migration and Invasion: Evidence from In Vitro Studies
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
ROS↓, SOD↓, GSTP1/GSTπ↓, NRF2↓, p62↓, p62↑, SOD↑, p‑mTOR↑, Beclin-1↓, ROS↑, SOD1↑,
267- ALA,    α-Lipoic Acid Targeting PDK1/NRF2 Axis Contributes to the Apoptosis Effect of Lung Cancer Cells
- vitro+vivo, Lung, A549 - vitro+vivo, Lung, PC9
Apoptosis↑, ROS↑, PDK1↓, NRF2↓, PDK1↓, Bcl-2↓, Casp9↑, Dose∅,
271- ALA,  VitC,  LDN,    The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol
OS↑, Weight↑, TumVol↓,
276- ALA,    Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B
P53↑, EMT↓, AMPK↑, cycD1/CCND1↓, TumCMig↓,
274- ALA,  LDN,    Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases
- Human, PC, NA
OS↑,
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
1235- ALA,  Cisplatin,    α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway
- in-vitro, Nor, HEI-OC1 - ex-vivo, NA, NA
ROS↑, HO-1↓, *toxicity↓, chemoP↑, *ROS↓, *HO-1↑, *SOD1↑, *NRF2↑,
4283- ALC,    Rapid-acting antidepressant-like effects of acetyl-l-carnitine mediated by PI3K/AKT/BDNF/VGF signaling pathway in mice
- in-vivo, NA, NA
*BDNF↑, *p‑Akt↑, *PI3K↑,
5320- ALC,    l-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer
- in-vivo, Var, NA
Strength↑, *Casp3↓, cachexia↓, *Dose↝,
5323- ALC,    Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy
- Trial, Var, NA
Pain↓, NP/CIPN↓,
5324- ALC,    The anti-wasting effects of L-carnitine supplementation on cancer: experimental data and clinical studies
- Review, Var, NA
*cachexia↓, *Apoptosis↓, *Inflam↓, QoL↑, Dose↝, Weight↑, OS↝, fatigue↓, eff↝,
5325- ALC,    L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial
- Trial, PC, NA
Weight↑, QoL↑, OS↑,
5326- ALC,    L-Carnitine Is an Endogenous HDAC Inhibitor Selectively Inhibiting Cancer Cell Growth In Vivo and In Vitro
- vitro+vivo, Liver, HepG2
TumCG↓, P21↑, ac‑H3↑, HDAC↓, *ATP↑, selectivity↑, ac‑H4↑,
5322- ALC,    Comparison of pharmacokinetics of L-carnitine, Acetyl-L-carnitine and Propionyl-Lcarnitine after single oral administration of L-carnitine in healthy volunteers
- Human, Nor, NA
*Half-Life↝,
5321- ALC,    L-Carnitine
- Review, Var, NA
fatigue↝, *Dose↝, NP/CIPN↓,
5315- ALC,    Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy
- Trial, BC, NA
other↑, NP/CIPN↑,
5316- ALC,    Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine
- Trial, BC, NA
NP/CIPN↑,
5317- ALC,    Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2
- in-vivo, Nor, NA
*BBB↝,
5318- ALC,    Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis
- Review, Var, NA
fatigue↝,
5319- ALC,    l-carnitine and cancer cachexia: Clinical and experimental aspects
- Review, Var, NA
fatigue↓, QoL↑, *GSH↑, Dose↝,
3974- ALC,    Carnitine
- Review, AD, NA
*Dose↝, *cognitive↑,
3975- ALC,    Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease
- Trial, AD, NA
*cognitive↑,
3976- ALC,    Acetyl-L-carnitine for dementia
- Review, AD, NA
*cognitive↝, *Mood↝,
3859- ALC,    Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment
- Review, AD, NA
*ROS↓, *ADAM10↑,
3435- aLinA,    Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa - in-vitro, Cerv, C33A
DNMTs↓, HDAC↓, HATs↑, hTERT/TERT↓, CDH1↑, RARβ↑, DNMT1↓, DNMT3A↓, TET2↑, HDAC1↓, HDAC8↓, SIRT1↓, HMTs↑, EZH2↓,
4512- aLinA,  GLA,    Evening primrose oil: a comprehensive review of its bioactives, extraction, analysis, oil quality, therapeutic merits, and safety
- in-vivo, Nor, NA
*other↝,
1252- aLinA,    α-Linolenic acid induces apoptosis, inhibits the invasion and metastasis, and arrests cell cycle in human breast cancer cells by inhibiting fatty acid synthase
- in-vitro, BC, NA
FASN↓, Apoptosis↑, TumCI↓, TumMeta↓, TumCCA↑,
1253- aLinA,    The Antitumor Effects of α-Linolenic Acid
- Review, NA, NA
PPARγ↑, COX2↓, E6↓, E7↓, P53↑, p‑ERK↓, p38↓, lipid-P↑, ROS⇅, MPT↑, MMP↓, Cyt‑c↑, Casp↑, iNOS↓, NO↓, Casp3↑, Bcl-2↓, Hif1a↓, FASN↓, CRP↓, IL6↓, IL1β↓, IFN-γ↓, TNF-α↓, Twist↓, VEGF↓, MMP2↓, MMP9↓,

Showing Research Papers: 551 to 600 of 6604
Prev Page 12 of 133 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6604

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSTP1/GSTπ↓, 1,   H2O2↑, 1,   HO-1↓, 1,   lipid-P↑, 1,   MDA↓, 1,   NRF2↓, 2,   ROS↓, 2,   ROS↑, 7,   ROS⇅, 1,   mt-ROS↑, 2,   SOD↓, 1,   SOD↑, 1,   SOD1↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   MPT↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 5,   FASN↓, 2,   FDG↓, 1,   PDH↑, 1,   PDK1↓, 2,   PPARγ↑, 1,   RARβ↑, 1,   SIRT1↓, 1,  

Cell Death ⓘ

Akt↓, 5,   p‑Akt↓, 1,   Apoptosis↑, 7,   BAX↑, 3,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Bcl-xL↓, 2,   BIM↑, 1,   Casp↑, 2,   Casp3↑, 4,   Casp9↑, 2,   Cyt‑c↑, 2,   GRP58↓, 1,   hTERT/TERT↓, 1,   iNOS↓, 1,   JNK↑, 1,   MAPK↓, 1,   Mcl-1↓, 1,   p27↑, 2,   p38↓, 1,   p38↑, 1,   survivin↓, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

EZH2↓, 1,   ac‑H3↑, 1,   ac‑H4↑, 1,   HATs↑, 1,   other↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,   p62↓, 1,   p62↑, 1,   TumAuto↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   DNMT1↓, 1,   DNMT3A↓, 1,   DNMTs↓, 1,   P53↓, 1,   P53↑, 4,   p‑P53↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

Cyc↓, 1,   cycD1/CCND1↓, 1,   P21↑, 2,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,   ERK↓, 2,   p‑ERK↓, 1,   HDAC↓, 2,   HDAC1↓, 1,   HDAC8↓, 1,   HMTs↑, 1,   IGF-1R↓, 1,   mTOR↓, 3,   p‑mTOR↑, 2,   p‑P70S6K↑, 1,   STAT3↓, 1,   TumCG↓, 8,  

Migration ⓘ

CDH1↑, 1,   E-cadherin↑, 1,   Furin↓, 1,   ITGB1↓, 1,   Ki-67↓, 1,   MMP11↓, 1,   MMP2↓, 1,   MMP9↓, 2,   MUC4↓, 1,   NeuroT↓, 1,   p‑SMAD2↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCI↓, 3,   TumCMig↓, 4,   TumCP↓, 3,   TumMeta↓, 1,   Twist↓, 2,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   EGR4↓, 1,   Hif1a↓, 1,   NO↓, 1,   PDI↑, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   CRP↓, 1,   IFN-γ↓, 1,   IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 1,   NF-kB↑, 1,   TNF-α↓, 2,  

Hormonal & Nuclear Receptors ⓘ

BNP↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,   Dose↑, 1,   Dose↝, 3,   Dose∅, 1,   eff↓, 1,   eff↑, 1,   eff↝, 1,   Half-Life↓, 1,   selectivity↑, 1,   TET2↑, 1,  

Clinical Biomarkers ⓘ

CRP↓, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 1,   EZH2↓, 1,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   Ki-67↓, 1,  

Functional Outcomes ⓘ

cachexia↓, 1,   chemoP↑, 1,   fatigue↓, 2,   fatigue↝, 2,   NP/CIPN↓, 2,   NP/CIPN↑, 2,   OS↑, 4,   OS↝, 1,   Pain↓, 1,   QoL↑, 3,   Strength↑, 1,   TumVol↓, 1,   Weight↑, 3,  
Total Targets: 151

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GSH↑, 2,   HO-1↑, 1,   lipid-P↓, 1,   NRF2↑, 1,   ROS↓, 3,   SOD1↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,  

Core Metabolism/Glycolysis ⓘ

GlucoseCon↑, 1,  

Cell Death ⓘ

p‑Akt↑, 1,   Apoptosis↓, 1,   Casp3↓, 1,  

Transcription & Epigenetics ⓘ

Ach↑, 1,   other↓, 1,   other↝, 2,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↑, 1,  

Barriers & Transport ⓘ

BBB↝, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,  

Synaptic & Neurotransmission ⓘ

ADAM10↑, 1,   BDNF↑, 1,   ChAT↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   BioAv↝, 1,   Dose↝, 3,   Half-Life↓, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

cachexia↓, 1,   cognitive↑, 2,   cognitive↝, 1,   memory↑, 1,   Mood↝, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 37

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page